西妥昔单抗联合FOLFOX4与单用FOLFOX4方案治疗晚期结肠癌临床疗效观察

目的观察比较西妥昔单抗联合FOLFOX4化疗方案与单用FOLFOX4化疗方案一线治疗晚期结肠癌的临床疗效和毒副反应。方法 26例经组织病理学证实的晚期结肠癌患者入选治疗组,采用西妥昔单抗联合FOLFOX4化疗方案化疗。对照组患者亦为26例,单用FOLFOX4方案进行化疗,观察比较两组化疗方案的近期疗效和不良反应。结果两组方案治疗晚期结肠癌的临床有效率(CR+PR)分别为53.8%和38.5%,其中联合化疗方案治疗效果明显优于单用FOLFOX4化疗方案,两组比较差异有统计学意义(P<0.05)。患者出现的不良反应有痤疮样皮疹、腹泻、骨髓抑制、恶心呕吐、神经毒性等。除痤疮样皮疹外,两组患者毒副反应无显著性差异。结论西妥昔单抗联合FOLFOX4化疗方案治疗晚期结肠癌近期疗效显著。毒副反应较单用FOLFOX4方案无明显增加,患者可以耐受。

Objective To observe the clinical efficacy and toxicity of chemotherapy of Cetuximab combined with FOLFOX4 compare with FOLFOX4 alone in the treatment of patients with advanced colorectal cancer.Methods 26 histopathology confirmed patients with advanced colorectal cancer were separate into treatment group who received the treatment of Cetuximab plus FOLFOX4,another 26 patients were separate into the control group who received the treatment of FOLFOX4 alone.Results The clinical efficacy（CR＋PR） of these two groups were 49.5% and 38.3%.The method of Cetuximab combined with Folfox4 is superior to the method of FOLFOX4alone.differences between these two groups was statistically significant（P0.05）.the mainly adverse reaction of these patients were exanthems,hypersensitive response,marrow suppression and neurotoxicity.Conclusion The efficacy of Cetuximab combined with FOLFOX4 is significant for the patients with advanced colorectal cancer.The toxicity between these two groups is similar and the patients can be tolerated.